Trial Initiated to Measure Efficacy of T-Cell Therapy in Secondary Progressive MS
Opexa Therapeutics is initiating a phase IIb trial of a novel therapy that targets T-cells in patients with secondary progressive multiple sclerosis.
This article was originally published on the Specialty Pharmacy Times website.
On May 13, 2014, biotechnology company Opexa Therapeutics
According to
In a press release, Chief Executive Officer of Opexa Neil K. Warma stated, “Interest from physicians and patients to participate in the study was high, underscoring the need for innovative treatments for Secondary Progressive MS, an area of high unmet medical need.”
Although many treatments are available for patients with relapsing forms of MS, treatment of progressive forms of MS are currently limited to symptom management.
The 2-year study will be conducted at 35 clinical centers across the United States and Canada. Patients will receive 5 subcutaneous injections of imilecleucel-T over a 24-week period at a dose of 30 to 45 million cells per 2-mL injection.
Each 24-week course of therapy will be administered twice yearly. Results are expected in December 2015, although data collection and processing may delay publication of results until 2016.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025